ACE and diabetic kidney disease: Until recently, the renin–angiotensin–aldosterone system blockade, with angiotensin-converting-enzyme inhibitors (ACEis) and angiotensin receptor blockers (ARBs), was the sole treatment option for diabetic kidney disease (DKD) [5].